登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603939 证券简称：益丰药房 公告编号：2025-068 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 关于部分募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 益丰大药房连锁股份有限公司（以下简称"公司"）募集资金投资项目"益丰数字化平台升级项目"（以下 简称"数字化项目"）的建设完成日期由2025年7月31日延长至2025年12月31日。募投项目的实施主体、 实施方式、募集资金投入总额及用途均无变化。 本次募集资金投资项目延期无需提交股东会审议。 公司于2025年7月30日召开第五届董事会第十九次会议和第五届监事会第十三次会议审议通过了《关于 部分募集资金投资项目延期的议案》，同意将"数字化项目"的建设完成日期延长至2025年12月31日。公 司监事会对此发表了明确同意的意见，保荐人对本事项出具了明确同意的核查意见。现将有关情况公告 如下： 一、募集资金基本情况 根据中国证券监督管理委员 ...

Core Points - The board of directors of Yifeng Pharmacy held its 19th meeting of the 5th session on July 30, 2025, with all 9 directors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][4] - The board approved several key proposals, including the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][5] - The board also approved the extension of the completion date for the "Yifeng Digital Platform Upgrade Project" from July 31, 2025, to December 31, 2025, without changing the project implementation subject, method, total amount of raised funds, or purpose [3][4] - A proposal was made to use up to 7.05 million yuan of the company's own funds to cover certain costs related to the digital platform upgrade project, with plans to replace these funds with equivalent amounts from the raised funds [3][4] - The company will hold its second extraordinary general meeting of 2025 on August 25, 2025, at 14:30, in Changsha, Hunan Province, with the board authorized to handle related matters [5]

重要内容提示： 证券代码：603939 证券简称：益丰药房 公告编号：2025-069 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 关于使用自有资金支付募投项目部分款项并以募集资 金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ?益丰大药房连锁股份有限公司（以下简称"公司"）拟在"益丰数字化平台 升级项目"（以下简称"数字化项目"）实施期间以不超过 705.00 万元募集资金等 额置换自有资金先行支付的相关支出，该部分等额置换资金视同募投项目使用资金。 ?本次募集资金等额置换的事项无需提交股东会审议。 公司于 2025 年 7 月 30 日召开第五届董事会第十九次会议和第五届监事会第十 三次会议审议通过了《关于使用自有资金支付募投项目部分款项并以募集资金等额 置换的议案》。公司监事会对此发表了明确同意的意见，保荐人对本事项出具了明 确同意的核查意见。现将有关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意益丰大药房连锁股份有限公司向不特 定对象发行可 ...

证券代码：603939 证券简称：益丰药房 公告编号：2025-068 债券代码：113682 债券简称：益丰转债 益丰大药房连锁股份有限公司 关于部分募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意益丰大药房连锁股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2024〕109 号），本公司由 主承销商中信证券股份有限公司采用余额包销方式，向社会公众公开发行可转换公 司债券 1,797.4320 万张，每张面值为人民币 100.00 元，按面值发行，共计募集资金 司募集资金监管账户。另减除上网发行费、招股说明书印刷费、申报会计师费、律 师费、评估费等与发行权益性证券直接相关的新增外部费用 469.99 万元，加上发行 费用中可抵扣的增值税进项税人民币 103.02 万元后，公司本次募集资金净额为 验证，并由其出具《验资报告》（天健验〔2024〕2-3 号）。 二、募集资金使用情况 截至 2025 年 ...

Group 1 - The core viewpoint of the article is that Yifeng Pharmacy has decided to extend the completion date of its digitalization project from July 31, 2025, to December 31, 2025, due to the complexity and interconnectivity of the systems involved [5][6]. - The total investment for the digitalization project is 80.642 million yuan, with the company planning to use the same amount from the raised funds [3]. - As of June 30, 2025, the company has invested 73.621 million yuan in the digitalization project, achieving a progress rate of 91.29% [3]. Group 2 - The delay in the project is attributed to the challenges in integrating various systems such as product, logistics, finance, and human resources, which has led to a postponement in platform integration and promotion [4]. - The company has confirmed that the extension will not change the project implementation entity, method, total investment amount, or usage of the raised funds, ensuring that it aligns with the long-term development plan and interests of shareholders [5][6]. - The board of directors and the supervisory board have approved the extension, affirming that the decision complies with relevant laws and regulations [6].

Core Viewpoint - The company intends to use its own funds to pay for part of the investment project and subsequently replace it with raised funds, which is in compliance with regulatory requirements and aims to enhance the efficiency of fund utilization [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds, with net fundraising amounting to approximately 253.43 million yuan after deducting related expenses [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects, including the Jiangsu Phase II, Hubei Pharmaceutical Sorting and Processing Center, and Hebei Pharmaceutical Warehouse, amounts to 253.43 million yuan, with 179.74 million yuan allocated from the raised funds [2]. Reasons for Using Own Funds - The company faces challenges in using raised funds directly for certain expenses, such as employee salaries and social insurance, which must be paid through the basic deposit account. Therefore, it plans to use up to 7.05 million yuan of its own funds for these payments and later replace them with raised funds [3][4]. Impact on the Company - The use of self-funds for project payments and subsequent replacement with raised funds is expected to improve fund utilization efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of the projects [4][5]. Review Procedures and Opinions - The company's board and supervisory committee have approved the proposal to use self-funds for the investment project, confirming that this action does not harm the interests of the company or its shareholders and complies with relevant regulations [5].

Core Viewpoint - Yifeng Pharmacy has extended the completion date of its fundraising project "Yifeng Digital Platform Upgrade Project" from July 31 to December 31, 2023, due to the complexity and challenges in integrating multiple systems [1] Group 1: Project Details - The implementation subject, method, total amount of raised funds, and usage remain unchanged despite the extension of the completion date [1] - The digital project involves integrating various systems including goods, logistics, finance, and human resources, which has led to delays in platform integration and promotion [1] Group 2: Challenges and Risks - The project faces challenges due to the strong interrelation of its components and the difficulty in collaboration, which has contributed to the delay [1] - Some hardware and software systems are deeply integrated with frontline business departments, necessitating thorough testing and feedback to avoid disconnects with actual business operations [1] - Certain remaining funds for personnel salaries, social insurance, and taxes cannot be paid directly from the fundraising account and need to be temporarily covered by the company's own funds, which will later be replaced by the raised funds [1] Group 3: Strategic Adjustments - The company aims to enhance the efficiency of fund usage and reduce investment risks by carefully evaluating the current progress of the fundraising project before deciding on the extension [1]

（编辑 任世碧） 证券日报网讯 7月30日晚间，益丰药房发布公告称，公司于2025年7月30日召开第五届董事会第十九次 会议和第五届监事会第十三次会议审议通过了《关于部分募集资金投资项目延期的议案》，同意将募集 资金投资项目"益丰数字化平台升级项目"的建设完成日期延长至2025年12月31日。 ...